II - In-house lobbyists and trade/business/professional associations
Companies & groups
One Amgen Center Drive
Thousand Oaks, California 91320-1799
Avenue Ariane, 5
Mr Robert Bradway
Chairman and Chief Executive Officer
Mr Douglas Gregory
Executive Director European Government Affairs
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Engage governments and policy makers worldwide on issues important to Amgen to:
Ensure patients have access to medicines they need
Provide coverage and reimbursement that reward innovation
Introduce sound, science-based regulation
Enable biotechnology research and development (R&D)
100%: 1 75%: 2 50%: 3 25%: 3
Following the Transparency Register implementing guidelines, released on 21 January 2015, Amgen has reviewed its financial data regarding activities under the scope of Article 7 of the Inter-Institutional Agreement published in the official journal of 19 September 2014.
The estimated annual costs arising from activities covered by the Register cover direct and indirect lobbying.
Amgen calculated our total costs (as per the TR guidelines) by adding up the following elements:
1. Staff costs: based on the full-time equivalents (FTEs) already declared.
2. Office and administrative expenses: rent and utilities, supplies and materials.
3. In-house operational expenditure: cost of advocacy, PR or public affairs campaigns, marketing and advertising, use of media, organisation of events, publications, etc.
4. Representation costs: expenses incurred through taking part in events and meetings.
5. Outsourced activity costs: fees for consultants and subcontractors.
6. Membership and related fees: fees for joining relevant networks and structures.
7. Other relevant costs
This new estimate follows and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
|First name||Surname||Start Date||End Date|
|JOANA MARIA||GANDARA LEITAO PAIVA||23/01/2015||20/01/2016|
Amgen is a member of the following organizations in Brussels:
Ad Hoc Council
American Chamber of Commerce to the EU
EBE – European Biopharmaceutical Enterprises
EFPIA – European Federation of Pharmaceutical Industries and Associations
European Policy Centre
Transatlantic Policy Network
01/2014 - 12/2014
1,250,000 € - 1,499,999 €
Research Framework Programme number 7: Kidney Connect 2013
By its registration the organisation has signed the Transparency Register Code of Conduct.